Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series LLC LTD Events with over 1000+ Conferences, 1000+ Symposiums and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series LLC LTD : World’s leading Event Organizer

Back

 Irach B Taraporewala

Irach B Taraporewala

President
Sitara Pharmaceutical Consulting Group
USA

Biography

Dr. Irach B. Taraporewala has over 30 years’ experiece in drug discovery/drug development R&D. He currently is President of the Sitara Pharmaceutical Consulting Group. He previously served as founder, CEO, President and Chief Technology Officer, and on the Board of Directors of OHR Pharmaceutical, Inc. an ophthalmology drug development company, and as a Drug Development consultant at PAREXEL Consulting. Dr. Taraporewala has published papers in drug development and delivery in reputed journals and has lectured extensively. He received a Ph.D. in Medicinal Chemistry from the Philadelpjhia College of Pharmacy and Science, and has been Principal Investigator on several NIH/DoD biomedical research grants.

Research Interest

Consulting on Pharmaceutical Company start-up and phased growth strategic planning, Drug Development and Regulatory Strategy, Risk management, CMC Regulatory Affairs, CMC Module 2 and 3 CTD submissions and review, Drug Master File submissions for APIs, GMP, Medicinal Chemistry, Drug Design, Organic Synthesis, Drug Discovery and Development, Quality Assurance, Quality Systems, Technology/intellectual Property Due Diigence for Mergers and Acquisitions, Pharmaceutical Portfolio Assessment , Formulation Development, Sustained Release Pharmaceuticals, Drug-Device Combination Products, SBIR/STTR Grants and IP Evaluations. Specialist on guiding success-driven strategy and regulatory pathway development to small and mid-sized pharmaceutical and biotech companies transitioning from the R&D stage to preclinical and clinical phases of drug development. Consultant services for strategic partnerships, due diligence for technology/IP evaluation on Mergers & Acquisitions, and on portfolio companies for venture firms.